Coastal Neurological Medical Group, Inc., La Jolla, California 92037, USA.
Int J Neurosci. 2011 Sep;121(9):485-9. doi: 10.3109/00207454.2011.582240. Epub 2011 Jun 15.
Bradykinesia has a significant impact on the lives of Parkinson's disease (PD) patients. Consequently, treating this symptom is of particular concern for patients and clinicians. A number of studies have documented the efficacy of rasagiline in reducing the severity of PD symptoms.
To summarize studies that specifically examined the impact of rasagiline on bradykinesia symptoms in PD patients across disease severity.
The EMBASE database was searched for relevant articles published between 2000 and November 2010.
Three studies were identified that explicitly examined the effect of rasagiline on the bradykinesia subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination. In each, 1 mg/day rasagiline significantly reduced bradykinesia scores in patients.
As a monotherapy or an adjunctive therapy, rasagiline is an effective drug for reducing the severity of bradykinesia in PD patients.
运动徐缓对帕金森病（PD）患者的生活有重大影响。因此，治疗这种症状是患者和临床医生特别关注的问题。多项研究证明雷沙吉兰可有效减轻 PD 症状的严重程度。
总结专门研究雷沙吉兰对不同严重程度 PD 患者运动徐缓症状影响的研究。
检索 EMBASE 数据库，查找 2000 年至 2010 年 11 月期间发表的相关文章。
共确定了 3 项专门研究雷沙吉兰对帕金森病评定量表（UPDRS）运动检查运动徐缓亚量表影响的研究。每日 1mg 雷沙吉兰治疗均显著降低了患者的运动徐缓评分。
作为单一疗法或辅助疗法，雷沙吉兰是一种有效减轻 PD 患者运动徐缓严重程度的药物。
